Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Acquires Two Cancer Treatment Agents in Late Stage Development for Relapsed AML and Cervical and Vaginal Cancers

PRWeb Wire - July 2011

Nanotherapeutics acquired two cancer treatment drugs that are in late stage development. Cloretazine®, formerly known as Onrigen™ for the treatment of relapsed acute AML and Triapine® for solid tumors such as cervical and vaginal cancers.

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.